WARREN, N.J., Aug. 19, 2025 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone…
WARREN, N.J., Aug. 19, 2025 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone…
No Comments
Leave a comment Cancel